<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03187379</url>
  </required_header>
  <id_info>
    <org_study_id>16-1571</org_study_id>
    <nct_id>NCT03187379</nct_id>
  </id_info>
  <brief_title>Efficacy of Exparel (TM) on Post-operative Pain After Laparoscopic Gastric Bypass Using Circular EEA Stapler</brief_title>
  <official_title>Efficacy of Exparel (TM) on Post-operative Pain After Laparoscopic Gastric Bypass Using Circular EEA Stapler</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>The Cleveland Clinic</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>The Cleveland Clinic</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      This will be a comparative study between two cohorts of patients undergoing Roux-en-Y Gastric
      bypass. One cohort (75 patients) will receive FDA approved Exparel® (liposome bupivacaine
      injection solution) injections intra-operatively at time of incision site closure. The
      control cohort (75 patients) will receive 0.25% bupivacaine injection solution at the time of
      incision site closure. The medication for the control group is our current standard of care.
      The primary end point is post-operative pain at 24 and 48 hours measured by the Visual Analog
      Scale (VAS). Comparison will be made between cohorts. All subjects enrolled in the study will
      be evaluated per nursing protocol with the verbal numerical analog scale. At 24 and 48 hours
      a member of the research team will administer a 2-part questionnaire containing the VAS and
      the Revised American Pain Society Post-Operative Questionnaire (APS-POQ-R). The latter is
      validated for assessment of the patient's experience of pain and it hindrance to daily
      activity in the post operative period.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The study will include up to 150 patients, and will consist of two cohort. The study cohort
      will include 75 patients who receive intraoperative Exparel® injections at the incision
      locations in addition to our standard multimodality post-operative analgesia. The control arm
      will include 75 patients who meet inclusion criteria but receive standard 0.25% bupivacaine
      and our standard multimodality post-operative analgesia. Patients will be randomized by
      REDCap™ database system in collaboration with Cleveland Clinic Pharmacy to receive either
      Exparel® or the control medication (0.25% Bupivacaine). Consent from patients will be
      obtained and documented by a dedicated research personnel prior to any enrollment.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">June 1, 2017</start_date>
  <completion_date type="Anticipated">December 31, 2018</completion_date>
  <primary_completion_date type="Anticipated">December 31, 2018</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Post-Operative Pain</measure>
    <time_frame>24 hours post-surgery</time_frame>
    <description>Patient-reported pain levels, on a 0-10 Visual Analog Scale (VAS)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Post-Operative Pain</measure>
    <time_frame>48 hours post-surgery</time_frame>
    <description>Patient-reported pain levels, on a 0-10 Visual Analog Scale (VAS)</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">150</enrollment>
  <condition>Post-operative Pain Management</condition>
  <arm_group>
    <arm_group_label>Exparel, Liposomal Bupivacaine</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects in this arm will receive Exparel® liposomal bupivacaine injected concurrently with 0.25% bupivacaine at the incisional sites prior to closing</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Control</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Subjects in this arm will receive 0.25% bupivacaine alone</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Exparel</intervention_name>
    <description>Exparel liposomal bupivacaine - 20cc Exparel® + 60cc Bupivicaine</description>
    <arm_group_label>Exparel, Liposomal Bupivacaine</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Bupivacaine</intervention_name>
    <description>60cc Bupivacaine</description>
    <arm_group_label>Control</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  bariatric surgery patients

          -  laparoscopic roux-en-y gastric bypass

          -  use of EEA stapler anastomosis

        Exclusion Criteria:

          -  age &lt;18 years

          -  previous history of roux-en-y gastric bypass

          -  patients undergoing other bariatric procedures

          -  pre-operative opioid analgesics
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>John Rodriguez, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>The Cleveland Clinic</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Linda Libertini</last_name>
    <phone>216-445-4148</phone>
    <email>libertl@ccf.org</email>
  </overall_contact>
  <location>
    <facility>
      <name>Cleveland Clinic</name>
      <address>
        <city>Cleveland</city>
        <state>Ohio</state>
        <zip>44195</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Linda Libertini</last_name>
      <phone>216-445-4148</phone>
      <email>libertl@ccf.org</email>
    </contact>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>June 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>June 1, 2017</study_first_submitted>
  <study_first_submitted_qc>June 12, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">June 14, 2017</study_first_posted>
  <last_update_submitted>June 12, 2017</last_update_submitted>
  <last_update_submitted_qc>June 12, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">June 14, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>The Cleveland Clinic</investigator_affiliation>
    <investigator_full_name>John Rodriguez, MD</investigator_full_name>
    <investigator_title>Associate Staff</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pain, Postoperative</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Bupivacaine</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

